Tag Archives: institute

Blood tests could detect sexually-transmitted oral cancers

Antibodies to a high-risk type of a virus that causes mouth and throat cancers when transmitted via oral sex can be detected in blood tests many years before onset of the disease, according to a World Health Organisation-led team of researchers. In a study in the Journal of Clinical Oncology, the researchers said their findings may in future lead to people being screened for human papillomavirus (HPV) antibodies, giving doctors a chance to find those at high risk of oral cancers. “Up to now, it was not known whether these antibodies were present in blood before the cancer became clinically detectable,” said Paul Brennan, of the WHO's International Agency for Research on Cancer (IARC), who led the study and described the findings as “very encouraging”. “If these results are confirmed, future screening tools could be developed for early detection of the disease,” he said. While HPV is better known for causing cervical and other genital cancers, it is also responsible for an increasing number of cancers of the mouth and throat, particularly amongst men. The issue was highlighted earlier this month by Hollywood actor Michael Douglas, who said his throat cancer was caused by HPV transmitted through oral sex. Oral, head and neck cancers are traditionally associated with heavy smoking and alcohol consumption, but over the past few decades rates of the diseases have increased dramatically, especially in Europe and North America. Brennan said this is probably due to HPV infections because of changing sexual practices, such as an increase in oral sex. According to IARC data, about 30 percent of all oral cancers are estimated to be HPV-related, and the main type of HPV associated with these tumours is HPV16. EARLIER DETECTION A study in the British Medical Journal in 2010 also found rates of head and neck cancer linked to HPV were rising rapidly, prompting calls from some doctors for boys as well as girls to be offered vaccinations to protect them against HPV. Two vaccines - Cervarix, made by GlaxoSmithKline, and Gardasil, made by Merck & Co - can prevent HPV. This new study, by scientists from IARC as well as the German Cancer Research Center and the U.S. National Cancer Institute, used data from a large study known as EPIC, which involves 500,000 people from 10 European countries who were recruited in the 1990s and have been followed up since. Researchers found that of the 135 people in the study who developed oral cancers, 47, or about one third of them, had HPV16 E6 antibodies up to 12 years before the onset of disease. In a telephone interview, Brennan said early detection would also allow doctors to track patients with antibodies and intervene early if tumours develop. “The earlier the detection, the better the treatment and the greater the survival,” he said. The antibody test used in the study was relatively simple and cheap and could be developed as a tool for more widespread screening within about five years if these results are confirmed in future studies, he added. He cautioned, however, that more work was needed to improve the tests' accuracy, since in this research there were about 1 in 100 “false positives” - where a person with the HPV16 antibodies did not go on to develop an oral cancer. Brennan said another significant finding of the study was that patients with oral cancers linked to HPV16 were three times more likely to be alive five years after their diagnosis than oral cancer patients whose tumours were not HPV-related and may have been linked to other risks such as smoking or drinking.source : http://www.foxnews.com/health/2013/06/18/blood-tests-could-detect-sexually-transmitted-oral-cancers/

Observation is safe, cost-saving in low-risk prostate cancer, study suggests

Writing in the June 18 issue of the Annals of Internal Medicine, the authors said their statistical models showed that "observation is a reasonable and, in some situations, cost-saving alternative to initial treatment" for the estimated 70 percent of men whose cancer is classified as low-risk at diagnosis. The researchers, led by Julia Hayes, MD, a medical oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber, said their findings support observation — active surveillance and watchful waiting — as a reasonable and underused option for men with low-risk disease. "About 70 percent of men in this country have low-risk prostate cancer, and it’s estimated that 60 percent of them are treated unnecessarily" with various forms of radiation or having the disease removed with radical prostatectomy surgery, said Hayes, who is also a senior scientist at MGH’s Institute for Technology Assessment. …

Cells play ‘tag’ to determine direction of movement

Scientists from Barcelona and London, looked at cells in the neural crest, a very mobile embryonic structure in vertebrates that gives rise to most of the peripheral nervous system and to other cell types in the cardiovascular system, pigment cells in the skin, and some bones, cartilage, and connective tissue in the head. Researchers saw that, during development, these neural crest cells ‘chase’ other types of cells — so-called placodal cells that give rise to the sensory organs — which dash away when approached, thus propelling the cell sheet in a certain direction. "The effect can also be likened to a donkey and carrot effect, with the neural crest cells — the donkey — chasing but never quite reaching the carrot, the placodal cells," explains Xavier Trepat, ICREA Research Professor of the UB and leader of the Research Group on Integrative Cell and Tissue Dynamics of IBEC…

To ease shortage of organs, grow them in a lab?

By the time 10-year-old Sarah Murnaghan finally got a lung transplant last week, she'd been waiting for months, and her parents had sued to give her a better shot at surgery. Her cystic fibrosis was threatening her life, and her case spurred a debate on how to allocate donor organs. Lungs and other organs for transplant are scarce. But what if there were another way? What if you could grow a custom-made organ in a lab? It sounds incredible. But just a three-hour drive from the Philadelphia hospital where Sarah got her transplant, another little girl is benefiting from just that sort of technology. Two years ago, Angela Irizarry of Lewisburg, Pa., needed a crucial blood vessel. Researchers built her one in a laboratory, using cells from her own bone marrow. Today the 5-year-old sings, dances and dreams of becoming a firefighter - and a doctor. Growing lungs and other organs for transplant is still in the future, but scientists are working toward that goal. In North Carolina, a 3-D printer builds prototype kidneys. In several labs, scientists study how to build on the internal scaffolding of hearts, lungs, livers and kidneys of people and pigs to make custom-made implants. Here's the dream scenario: A patient donates cells, either from a biopsy or maybe just a blood draw. A lab uses them, or cells made from them, to seed onto a scaffold that's shaped like the organ he needs. Then, says Dr. Harald Ott of Massachusetts General Hospital, “we can regenerate an organ that will not be rejected (and can be) grown on demand and transplanted surgically, similar to a donor organ.” That won't happen anytime soon for solid organs like lungs or livers. But as Angela Irizarry's case shows, simpler body parts are already being put into patients as researchers explore the possibilities of the field. Just a few weeks ago, a girl in Peoria, Ill., got an experimental windpipe that used a synthetic scaffold covered in stem cells from her own bone marrow. More than a dozen patients have had similar operations. Dozens of people are thriving with experimental bladders made from their own cells, as are more than a dozen who have urethras made from their own bladder tissue. A Swedish girl who got a vein made with her marrow cells to bypass a liver vein blockage in 2011 is still doing well, her surgeon says. In some cases the idea has even become standard practice. Surgeons can use a patient's own cells, processed in a lab, to repair cartilage in the knee. Burn victims are treated with lab-grown skin. In 2011, it was Angela Irizarry's turn to wade into the field of tissue engineering. Angela was born in 2007 with a heart that had only one functional pumping chamber, a potentially lethal condition that leaves the body short of oxygen. Standard treatment involves a series of operations, the last of which implants a blood vessel near the heart to connect a vein to an artery, which effectively rearranges the organ's plumbing. Yale University surgeons told Angela's parents they could try to create that conduit with bone marrow cells. It had already worked for a series of patients in Japan, but Angela would be the first participant in an American study. “There was a risk,” recalled Angela's mother, Claudia Irizarry. But she and her husband liked the idea that the implant would grow along with Angela, so that it wouldn't have to be replaced later. So, over 12 hours one day, doctors took bone marrow from Angela and extracted certain cells, seeded them onto a 5-inch-long biodegradable tube, incubated them for two hours, and then implanted the graft into Angela to grow into a blood vessel. It's been almost two years and Angela is doing well, her mother says. Before the surgery she couldn't run or play without getting tired and turning blue from lack of oxygen, she said. Now, “she is able to have a normal play day.” This seed-and-scaffold approach to creating a body part is not as simple as seeding a lawn. In fact, the researchers in charge of Angela's study had been putting the lab-made blood vessels into people for nearly a decade in Japan before they realized that they were completely wrong in their understanding of what was happening inside the body. “We'd always assumed we were making blood vessels from the cells we were seeding onto the graft,” said Dr. Christopher Breuer, now at Nationwide Children's Hospital in Columbus, Ohio. But then studies in mice showed that in fact, the building blocks were cells that migrated in from other blood vessels. The seeded cells actually died off quickly. “We in essence found out we had done the right thing for the wrong reasons,” Breuer said. Other kinds of implants have also shown that the seeded cells can act as beacons that summon cells from the recipient's body, said William Wagner, director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. Sometimes that works out fine, but other times it can lead to scarring or inflammation instead, he said. Controlling what happens when an engineered implant interacts with the body is a key challenge, he said. So far, the lab-grown parts implanted in people have involved fairly simple structures - basically sheets, tubes and hollow containers, notes Anthony Atala of Wake Forest University whose lab also has made scaffolds for noses and ears. Solid internal organs like livers, hearts and kidneys are far more complex to make. His pioneering lab at Wake Forest is using a 3-D printer to make miniature prototype kidneys, some as small as a half dollar, and other structures for research. Instead of depositing ink, the printer puts down a gel-like biodegradable scaffold plus a mixture of cells to build a kidney layer by layer. Atala expects it will take many years before printed organs find their way into patients. Another organ-building strategy used by Atala and maybe half a dozen other labs starts with an organ, washes its cells off the inert scaffolding that holds cells together, and then plants that scaffolding with new cells. “It's almost like taking an apartment building, moving everybody out ... and then really trying to repopulate that apartment building with different cells,” says Dr. John LaMattina of the University of Maryland School of Medicine. He's using the approach to build livers. It's the repopulating part that's the most challenging, he adds. One goal of that process is humanizing pig organs for transplant, by replacing their cells with human ones. “I believe the future is ... a pig matrix covered with your own cells,” says Doris Taylor of the Texas Heart Institute in Houston. She reported creating a rudimentary beating rat heart in 2008 with the cell-replacement technique and is now applying it to a variety of organs. Ott's lab and the Yale lab of Laura Niklason have used the cell-replacement process to make rat lungs that worked temporarily in those rodents. Now they're thinking bigger, working with pig and human lung scaffolds in the lab. A human lung scaffold, Niklason notes, feels like a handful of Jell-O. Cell replacement has also worked for kidneys. Ott recently reported that lab-made kidneys in rats didn't perform as well as regular kidneys. But, he said, just a “good enough organ” could get somebody off dialysis. He has just started testing the approach with transplants in pigs. Ott is also working to grow human cells on human and pig heart scaffolds for study in the laboratory. There are plenty of challenges with this organ-building approach. One is getting the right cells to build the organ. Cells from the patient's own organ might not be available or usable. So Niklason and others are exploring genetic reprogramming so that, say, blood or skin cells could be turned into appropriate cells for organ-growing. Others look to stem cells from bone marrow or body fat that could be nudged into becoming the right kinds of cells for particular organs. In the near term, organs might instead be built with donor cells stored in a lab, and the organ recipient would still need anti-rejection drugs. How long until doctors start testing solid organs in people

Using math to kill cancer cells

"Oncolytic viruses are special in that they specifically target cancer cells," explains Dr. Bell, a senior scientist at the Ottawa Hospital Research Institute and professor at the University of Ottawa’s Faculty of Medicine. "Unfortunately, cancer is a very complicated and diverse disease, and some viruses work well in some circumstances and not well in others. As a result, there has been a lot of effort in trying to modify the viruses to make them safe, so they don’t target healthy tissue and yet are more efficient in eliminating cancer cells." Dr. …

Protein protects against breast cancer recurrence in animal model

Precisely what causes breast cancer recurrence has been poorly understood. But now a piece of the puzzle has fallen into place: Researchers at the Perelman School of Medicine, University of Pennsylvania have identified a key molecular player in recurrent breast cancer — a finding that suggests potential new therapeutic strategies. The study, performed in the laboratory of Lewis A. …

Drugmakers to cooperate in safety review of diabetes drugs

Global drugmakers said on Wednesday they would cooperate with an independent review to address concerns of a potential link between widely used diabetes medicines and pancreatic cancer and other safety problems. The American Diabetes Association (ADA) this week called for a new evaluation of clinical data on drugs used to control blood sugar for patients with type 2 diabetes. They include Merck & Co's $4 billion a year Januvia franchise, Novo Nordisk's Victoza, and Byetta and Onglyza from Bristol-Myers Squibb Co and AstraZeneca Plc, among others. “People who are taking these medications, or who may consider taking them, should have the benefit of all that is currently known about their risks and advantages in order to make the best possible decisions about their treatment,” Dr. Robert Ratner, ADA's chief scientific and medical officer, said in a statement. The medicines are called incretin mimetics because they mimic hormones the body produces to stimulate release of insulin, and are from classes of drugs known as GLP-1 receptor agonists and DPP-4 inhibitors. GLP-1 drugs boost insulin production by the pancreas and slow absorption of food. DPP-4 inhibitors block an enzyme the breaks down the GLP-1 peptide in the gut, thereby increasing insulin production. The U.S. Food and Drug Administration in March said it was studying unconfirmed reports that the drugs cause inflammation of the pancreas and pre-cancerous changes to cells in the pancreas. European health regulators are also studying the issue. Around the same time, new concerns arose from a small study conducted by a leading diabetes expert, Dr. Peter Butler, from the University of California, Los Angeles. Butler examined human pancreases from patients who had died of causes unrelated to pancreatic disease and found more pancreas lesions and one cancerous tumor in those who had taken Januvia or Byetta compared with nondiabetics or diabetics who had not taken those medicines. More than 370 million people are living with diabetes worldwide, with type 2 accounting for 90 percent to 95 percent of the cases, according to the International Diabetes Federation. Without significant lifestyle changes to curb obesity and other causes of diabetes, that number could balloon to as many as 552 million by 2030, the organization projected. NO FIRM EVIDENCE OF RISK Bristol-Myers and AstraZeneca issued a joint statement expressing support for the ADA initiative. Merck said it is committed to participating in the ADA effort, and is separately conducting a 14,000-patient heart safety study of Januvia. Danish drugmaker Novo Nordisk, in an emailed comment, said its studies to assess safety signals of its $1.8 billion a year Victoza do not reveal any evidence of increased risk of pancreatitis or pancreatic cancer. “As far as the ADA proposal is concerned, this is something that I do support from a conceptual basis,” said Alan Moses, Novo's global chief medical officer, in a telephone interview. “In principle, Novo Nordisk absolutely supports working with the other companies, but the final details depend on what specifically is being proposed,” Moses said, adding “it all depends on the credibility of the data that's being evaluated.” The safety concerns are being discussed on Wednesday and Thursday at a workshop conducted by the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A document outlining the FDA's presentation at the workshop was handed out at the meeting. Attendees quoted it as saying the agency review of trial data on the drugs did not provide enough evidence to say whether there is a link to pancreatitis, and that long-term study would be required to determine any cancer risk. A FDA spokeswoman could not immediately confirm the contents of the document. “The FDA basically appears to just be saying 'look, there just isn't enough information here to make an informed decision',” said Mark Schoenebaum, a drug industry analyst with ISI Group who was attending to two-day NIH/NIDDK workshop. “There are no conclusions at this point in time from the meeting and I doubt very much there will be because the science quite frankly is immature about the whole area of pancreatic cancer,” said Novo's Moses, who will address the workshop on Thursday. “Everybody agrees that this is an incredibly complex area.” In an interview with Reuters earlier this week Peter Stein, Merck vice president of clinical research for diabetes, expressed full confidence in the safety of Januvia. During the workshop, Merck said it will present data on the safety profile of Januvia, known chemically as sitagliptin, including an updated analysis of data from more than 14,000 patients from 25 randomized clinical trials. Merck last month reported a surprising decline in first quarter sales of Januvia, which has been the drugmaker's fastest growing medicine since its 2006 approval. It was not clear if increased competition, safety concerns or other factors led to the 4 percent slip in quarterly sales to $884 million.source : http://www.foxnews.com/health/2013/06/13/drugmakers-to-cooperate-in-safety-review-diabetes-drugs/